DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by…
DEM BiopharmaALX OncologyWhitehead Institute for Biomedical ResearchDana-Farber Cancer InstituteBrigham and Women's HospitalStanford University School of MedicineStanford University School of MedicineUniversity of CambridgeAmherst College
Christoph Westphal
American businessman
DEM BiopharmaSolu TherapeuticsSelf-employedSirtris PharmaceuticalsLongwood FundImmunitas TherapeuticsHarvard Medical SchoolHarvard UniversityColumbia University
David Donabedian
CEO at Solu Therapeutics
AnunciaAlcyone TherapeuticsSolu TherapeuticsAlcyone LifesciencesDEM BiopharmaLongwood FundKenan-Flagler Business School UNC-Chapel HillUNC Kenan-Flagler Business SchoolSaint Anselm CollegeUniversity of Massachusetts Lowell
John Pribis
Founder at Solu Therapeutics
Solu TherapeuticsLongwood FundDEM BiopharmaFL77, IncBaylor College of MedicineUniversity of PittsburghBaylor College of MedicineDrexel University